ロード中...
BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis
BACKGROUND: Targeted therapies and immunotherapies are first-line treatments for patients with advanced melanoma. Serine–threonine protein kinase B-RAF (BRAF) and mitogen-activated protein kinase (MEK) inhibition leads to a 70% response rate in patients with advanced melanoma with a BRAF(V600E)(/K)...
保存先:
| 出版年: | J Immunother Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7482503/ https://ncbi.nlm.nih.gov/pubmed/32912923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000275 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|